Elinor J. Sawyer
A5064426212- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Genetic Associations and Epidemiology
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- Nutrition, Genetics, and Disease
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Gene expression and cancer classification
- Genomics and Chromatin Dynamics
- Bioinformatics and Genomic Networks
- Genomic variations and chromosomal abnormalities
- Epigenetics and DNA Methylation
- Cytokine Signaling Pathways and Interactions
- Cancer Risks and Factors
- Cancer and Skin Lesions
- RNA modifications and cancer
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- COVID-19 and healthcare impacts
- Genomics and Rare Diseases
- Molecular Biology Techniques and Applications
- Advanced Radiotherapy Techniques
King's College London
2016-2025
Guy's and St Thomas' NHS Foundation Trust
2014-2024
Breast Cancer Now
2002-2024
Guy's Hospital
2013-2023
St Thomas' Hospital
1997-2023
The London College
2018-2023
St. Thomas Hospital
2023
Cancer Research Center
2010-2021
London Cancer
2018-2021
University of Manchester
2018-2021
BackgroundWe aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior terms local cancer control and as safe an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results the FAST-Forward trial.MethodsFAST-Forward multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 centres 50 referring hospitals) UK. Patients aged least 18 years...
Previous studies have suggested that breast cancer risk factors are associated with estrogen receptor (ER) and progesterone (PR) expression status of the tumors.
Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 the risk of female cancer rs1314913 male cancer. The aim this study was investigate role RAD51B variants in predisposition, particularly context familial Finland. We sequenced coding region 168 Finnish patients from Helsinki for identification possible recurrent founder mutations. In addition, we studied known rs999737, rs2588809, SNPs haplotypes 44,791 cases 43,583 controls 40...
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or the miRNA binding sites may affect dependent gene expression regulation, which has been implicated various cancers, including breast cancer, and alter individual susceptibility to cancer. We investigated associations between related SNPs cancer risk. First we evaluated 2,196 a case-control study combining nine genome wide association studies (GWAS). Second, further 42 with suggestive evidence for using...
Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with having dismal survival. We sequenced whole genomes or a panel 365 genes on 299 samples from 170 locally relapsed cancer. Several lines analysis indicate that clones seeding metastasis relapse disseminate late tumors, but continue to acquire mutations, mostly accessing the same mutational processes active tumor. Most distant metastases acquired driver...
Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced patient age clinicopathological factors. We hypothesise that partial-breast restricted to the vicinity of original tumour women at lower than average local will improve balance beneficial versus adverse effects compared with whole-breast radiotherapy.
A family history of prostate cancer (PrCa) is a strong risk factor for the disease, indicating that inherited factors are important in this disease. We previously estimated about 2% PrCa cases diagnosed ≤ 55 years harbour BRCA2 mutation and among carriers has been shown to be more aggressive, with poorer survival.To further evaluate role predisposition, we screened 1864 men aged between 36 88 years. analysed gene using novel high-throughput multiplex fluorescence heteroduplex detection...
Observational epidemiological studies have shown that high body mass index (BMI) is associated with a reduced risk of breast cancer in premenopausal women but an increased postmenopausal women. It unclear whether this association mediated through shared genetic or environmental factors.
The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some these are with breast risk as high those rare BRCA2 mutations. We aimed the relative risks specific variants via a multicentre case-control study.
Abstract Breast, ovarian, and prostate cancers are hormone-related may have a shared genetic basis, but this has not been investigated systematically by genome-wide association (GWA) studies. Meta-analyses combining the largest GWA meta-analysis data sets for these totaling 112,349 cases 116,421 controls of European ancestry, all together in pairs, identified at P < 10−8 seven new cross-cancer loci: three associated with susceptibility to (rs17041869/2q13/BCL2L11;...
Rare germline genetic variants in several genes are associated with increased breast cancer (BC) risk, but their precise contributions to different disease subtypes unclear. This information is relevant guidelines for gene panel testing and risk prediction.To characterize tumors BC susceptibility large-scale population- or hospital-based studies.The multicenter, international case-control analysis of the BRIDGES study included 42 680 patients 46 387 control participants, comprising women...
CHEK2*1100delC is a well-established breast cancer risk variant that most prevalent in European populations; however, there are limited data on of by age and tumor subtype, which limits its usefulness prediction. We aimed to generate subtype- age-specific estimates using from the Breast Cancer Association Consortium, including 44,777 patients with 42,997 controls 33 studies genotyped for CHEK2*1100delC.
Abstract The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens tumor cells with CRISPR/Cas9-engineered CDH1 mutations, we identified synthetic lethality between deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic molecularly diverse lines established E-cadherin/ROS1 was only robust face considerable molecular...
Abstract Triple-negative breast cancers are an aggressive subtype of cancer with poor survival, but there remains little known about the etiologic factors that promote its initiation and development. Commonly inherited risk identified through genome-wide association studies display heterogeneity effect among subtypes as defined by status estrogen progesterone receptors. In Triple Negative Breast Cancer Consortium (TNBCC), 22 common susceptibility variants were investigated in 2,980 Caucasian...